Financial Performance - The company's revenue for Q1 2024 was ¥66,705,459.25, representing a 20.32% increase compared to ¥55,440,064.10 in the same period last year[5] - Net profit attributable to shareholders for Q1 2024 was ¥14,042,843.67, a 46.66% increase from ¥9,575,298.60 year-over-year[5] - The net profit after deducting non-recurring gains and losses was ¥12,061,082.58, showing a significant increase of 90.22% from ¥6,340,660.01 in the previous year[5] - Basic and diluted earnings per share for Q1 2024 were both ¥0.1738, reflecting a 46.67% increase compared to ¥0.1185 in the previous year[5] - The operating profit for the first quarter was CNY 16,305,235.17, up from CNY 11,043,044.54, indicating a growth of 47.5% year-over-year[24] - The total comprehensive income for the first quarter was CNY 14,042,843.67, compared to CNY 9,575,298.60 in the previous year, reflecting a 46.5% increase[25] Cash Flow - The net cash flow from operating activities reached ¥7,445,732.65, a remarkable turnaround from a negative cash flow of ¥632,674.43 in the same quarter last year, marking a 1,276.87% improvement[5] - Cash flow from operating activities generated a net inflow of CNY 7,445,732.65, a significant improvement from a net outflow of CNY -632,674.43 in the previous year[26] - Cash inflow from investment activities totaled CNY 238,619,544.48, down from CNY 404,918,801.08 in the same period last year[26] - Cash outflow for investment activities was CNY 232,351,716.60, compared to CNY 396,288,655.62 in the previous year[27] - The net cash flow from financing activities was CNY -61,366,187.07, indicating cash outflows related to financing[27] Assets and Liabilities - Total assets at the end of Q1 2024 were ¥1,002,981,793.10, a decrease of 6.02% from ¥1,067,195,971.50 at the end of the previous year[5] - The total liabilities decreased to RMB 67,390,209.11 from RMB 84,332,557.25, reflecting a reduction of 20.1%[22] - The company’s fixed assets increased to RMB 299,987,910.49 from RMB 236,483,272.86, an increase of 26.8%[21] - Cash and cash equivalents decreased to RMB 286,718,076.27 from RMB 334,370,419.58 at the beginning of the period, a decline of 14.2%[20] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 8,195[11] - The largest shareholder, Zhang Jun, holds 24.29% of the shares, totaling 19,627,034 shares[11] - The total number of restricted shares at the beginning of the period was 22,775,809, with no shares released or added during the reporting period[14] - The top ten shareholders hold a total of 22,775,809 shares, with the largest shareholder holding 19,627,034 shares[14] - The company has a significant number of shares held by major shareholders, with the largest shareholder, Zhang Jun, holding 19,627,034 shares, representing a substantial portion of the total[14] Strategic Developments - The company plans to establish a wholly-owned subsidiary, Jilin Xinqing Pharmaceutical Technology Co., Ltd., with an investment of RMB 10 million, which has completed the necessary registration procedures[15] - The company received a Supplementary Application Approval Notice from the National Medical Products Administration for its injectable Rosuvastatin Acetate[16] - The company is focused on expanding its market presence through new product approvals and subsidiary establishment[16] - The company is actively pursuing new product development and regulatory approvals to enhance its product portfolio[16] - The company has established a strategic relationship with several investment firms, indicating potential for future capital influx[12] Other Information - The company appointed Ms. Zhang Yinjie as the Vice General Manager and Secretary of the Board, effective from February 1, 2024[15] - The company has not reported any changes in the number of shares lent or returned in the securities lending business during the reporting period[12] - The company repurchased a total of 2,681,558 shares, representing 3.32% of the total share capital, with a total transaction amount of RMB 61,304,621.75[18] - The first quarter report was not audited, as indicated by the company[28]
西点药业(301130) - 2024 Q1 - 季度财报